Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 7/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.33 |
| ▸ | PPARD | Q03181 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.32 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.32 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4990976 | 0.93 | DPP4 (0.37) | DPP4DPP7RIPK1EPHX2PPARG | |
| SCHEMBL4993560 | 0.91 | EPHX2 (0.36) | RIPK1EPHX2PPARGDPP9PKM | |
| SCHEMBL4992979 | 0.91 | EPHX2 (0.36) | RIPK1EPHX2PPARGDPP9PKM | |
| SCHEMBL4986805 | 0.91 | EPHX2 (0.36) | RIPK1EPHX2PPARGDPP9PKM | |
| SCHEMBL4986198 | 0.91 | EPHX2 (0.36) | RIPK1EPHX2PPARGDPP9PKM | |
| SCHEMBL4985206 | 0.86 | RIPK1 (0.34) | DPP4DPP7RIPK1DPP9DPP8 | |
| SCHEMBL4986989 | 0.86 | DPP4 (0.35) | DPP4DPP7RIPK1DPP9DPP8 | |
| SCHEMBL4992635 | 0.86 | RIPK1 (0.34) | RIPK1GRIK1 | |
| SCHEMBL4983394 | 0.86 | TAAR1 (0.40) | PPARGPPARAGRIK1 | |
| SCHEMBL4989908 | 0.85 | DPP4 (0.43) | DPP4DPP7RIPK1EPHX2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050124668-A1 | Amino acids with affinity for the alpha2delta-protein | WARNER-LAMBERT COMPANY LLC | 2005-06-09 | — | — | US | claimed |
| US-7388023-B2 | Amino acids with affinity for the α2δ-protein | WARNER-LAMBERT COMPANY LLC (US) | 2008-06-17 | — | — | US | disclosed |
| US-20070129550-A1 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN | WANER-LAMBERT COMPANY LLC (US) | 2007-06-07 | — | — | US | disclosed |
| US-7179934-B2 | Amino acids with affinity for the α2δ-protein | WARNER-LAMBERT COMPANY LLC (US) | 2007-02-20 | — | — | US | disclosed |
| US-20050124668-A1 | Amino acids with affinity for the alpha2delta-protein | WARNER-LAMBERT COMPANY LLC | 2005-06-09 | — | — | US | disclosed |
| US-20050101643-A1 | Amino acids with affinity for the alpha2delta-protein | WARNER-LAMBERT COMPANY LLC | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124668-A1 | Amino acids with affinity for the alpha2delta-protein | SCN2A, SCN1A, OPRD1 | DPP4 2680/4885DPP7 1811/4885RIPK1 4443/4885 |
| US-20070129550-A1 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN | SCN2A, OPRD1, SCN1A | DPP4 3263/4885DPP7 2158/4885RIPK1 4295/4885 |
| US-20050101643-A1 | Amino acids with affinity for the alpha2delta-protein | SCN2A, OPRD1, SCN1A | DPP4 2672/4885DPP7 1690/4885RIPK1 4459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.